HER2-Positive Circulating Tumor Cells in Breast Cancer
Author Information
Author(s): Ignatiadis Michail, Rothé Françoise, Chaboteaux Carole, Durbecq Virginie, Rouas Ghizlane, Criscitiello Carmen, Metallo Jessica, Kheddoumi Naima, Singhal Sandeep K., Michiels Stefan, Veys Isabelle, Rossari José, Larsimont Denis, Carly Birgit, Pestrin Marta, Bessi Silvia, Buxant Frédéric, Liebens Fabienne, Piccart Martine, Sotiriou Christos
Primary Institution: Institut Jules Bordet, Brussels, Belgium
Hypothesis
To interrogate tumor cell dissemination during breast cancer progression by studying CTCs and HER2 expression across different stages.
Conclusion
HER2-positive CTCs were detected in early stages of breast cancer, indicating their potential role in monitoring disease progression.
Supporting Evidence
- No HER2-positive CTC was detected in 42 women without BC.
- 4.1% of women with DCIS/LCIS had HER2-positive CTCs.
- 7.9% of women with non-metastatic BC had HER2-positive CTCs.
- 35.9% of women with metastatic BC had HER2-positive CTCs.
Takeaway
The study found that some women with early breast cancer have special cells in their blood that can help doctors understand how the cancer is spreading.
Methodology
Blood samples from women with different stages of breast cancer were analyzed for HER2-positive CTCs using the CellSearch® technology.
Limitations
The study's findings should be interpreted with caution due to the low number of cases with HER2-positive CTCs.
Participant Demographics
Women with DCIS/LCIS, M0, and M1 breast cancer treated at various hospitals in Belgium.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI 0–8.4%
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website